Regeneron Pharmaceuticals reported positive phase III results for garetosmab, a fully human monoclonal antibody targeting activin A, showing significant reduction of new bone growth lesions in fibrodysplasia ossificans progressiva (FOP), an ultra-rare skeletal disorder characterized by abnormal bone formation. The success of the Optima trial positions Regeneron to file for FDA approval by year-end, potentially offering the first treatment for this life-limiting condition. Regeneron also revealed promising analyses for combination obesity therapies involving semaglutide and novel agents addressing lean mass loss.